After the Fed released minutes of its last meeting, the bond market signaled it fears the Fed will not be aggressive enough with its rate cutting.Market Insiderread more
The Fed minutes also note that "a couple" members wanted a 50 basis point cut, based primarily on the weak inflation readings.The Fedread more
Analysts generally doubt how effective the People Bank of China's latest interest rate announcement will be in significantly helping businesses grow.China Economyread more
Japanese manufacturing activity shrank for a fourth straight month in August as export orders fell at a sharper pace.Asia Marketsread more
These in-demand skills can command top pay packets, says Feon Ang of professional networking site LinkedIn.Get Aheadread more
The Washington governor had centered his campaign around climate change, calling it "the most urgent challenge of our time."Politicsread more
The inversion is seen by many veteran traders as an important recession omen, though the timing on the eventual downturn is less predictable.Bondsread more
Here's what Nordstrom reported for its fiscal second-quarter earnings.Retailread more
The sexy image that once boosted Victoria's Secret has been haunting L Brands more recently, as women are steering clear of the brand's hot pink, lacy and bejeweled lingerie.Retailread more
Ford is one of four automakers that reached a voluntary agreement with California on fuel efficiency rules, defying Trump and his administration's effort to strip the state of...Autosread more
See which stocks are posting big moves after the bell.Market Insiderread more
As Alnylam Pharmaceuticals nears approval of its first drug, the fledgling drug-maker is planning to transition out of research and development into the commercial stage.
That means figuring out a pricing strategy, and CEO John Maraganore said he supports the idea of pegging increases in drug prices to the rate of inflation.
"It's hard to justify drug price increases," Maraganore said on CNBC's "Power Lunch." If you price a drug appropriately, where it ought to be priced, whats the rationale of increasing the price every year? "
"It's hard for our industry to defend that, overall," he added.
That breaks down to a price increase of approximately 2 to 3 percent yearly, which pales in comparison to increases industry-wide. Drug costs have skyrocketed in recent years, with some prices surging more than 1,000 percent per year.
Companies argue profits from inflated drug pricing help them grow and fund more drug development. Alnylam hopes to take almost the opposite approach, growing through innovation.
"At Alnylam, we've got a really robust product engine. We have the ability of generating, with our platform, a steady flow of new medicines. We just don't have to rely on drug price increases as a way of fueling future growth for the company," he said.
Despite his optimism, the company had high-profile drug failures. Stock struggled late last year when the company was forced to halt development on drug revusiran, after a late-stage study revealed it increased risk of death in test subjects.
Still, Maraganore feels confident that Alnylam's next drug, patisiran, is nearing approval, and the company has a few additional drugs in the pipeline. Stock has responded accordingly, up more than 257 percent year-to-date.
Maraganore also looked ahead to what drug distribution could look like in the near future. Alnylam aims to be there when Amazon makes more decisive moves into the health-care industry, according to the CEO.
"It could be very disruptive from distribution model to have a company like Amazon in the space," Maraganore said. "We welcome a conversation with Amazon to ... understand how we can work together to make sure patients get access to important medicines."